Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note
Section:
 

Relative Value

526139 doesn't have a meaningful market cap.

The Relative Value of one TRABI stock under the Base Case scenario is 0.29 INR. Compared to the current market price of 6.94 INR, Transgene Biotek Ltd is Overvalued by 96%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TRABI Relative Value
Base Case
0.29 INR
Overvaluation 96%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

266
P/S
P/S
Price to Sales
266
vs History
44
vs Industry
9
Median 3Y
287.1
Median 5Y
258.7
Industry
7.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.3
Median 5Y
-3.1
Industry
22.1
More Details
6 537.1
P/OCF
P/OCF
Price to OCF
6 537.1
vs History
26
vs Industry
100
Median 3Y
6 075.5
Median 5Y
273.5
Industry
21.9
More Details
6 537.1
P/FCFE
P/FCFE
Price to FCFE
6 537.1
vs History
20
vs Industry
0
Median 3Y
274.8
Median 5Y
-588.5
Industry
23.4
More Details
4.9
P/B
P/B
Price to Book Value
4.9
vs History
14
vs Industry
13
Median 3Y
2.5
Median 5Y
1.6
Industry
2.5
More Details
336.5
EV/S
EV/S
Enterprise Value to Sales
336.5
vs History
46
vs Industry
7
Median 3Y
368.7
Median 5Y
318.3
Industry
7.5
More Details
337.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
337.2
vs History
38
vs Industry
4
Median 3Y
301.2
Median 5Y
305.5
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
1
Median 3Y
-68.8
Median 5Y
-63.6
Industry
4.2
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-7.5
Median 5Y
-4.3
Industry
4
More Details
8 271
EV/OCF
EV/OCF
Enterprise Value to OCF
8 271
vs History
26
vs Industry
100
Median 3Y
7 868.7
Median 5Y
396.1
Industry
5.9
More Details
8 271
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
8 271
vs History
20
vs Industry
0
Median 3Y
399.7
Median 5Y
276.6
Industry
3.9
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
14
vs Industry
64
Median 3Y
0.3
Median 5Y
0.3
Industry
4.5
More Details

Multiples Across Competitors

TRABI Competitors Multiples
Transgene Biotek Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Transgene Biotek Ltd
BSE:526139
525.8m INR 266 -203.8 -77.6 -70.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 5.7 62 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 4.4 33.5 16.1 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 4.1 923.6 10.3 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 9.8 -217.7 21.5 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.3 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 5.7 16.9 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.3 -109.3 -79.6
P/S Multiple
Revenue Growth P/S to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average P/S: 3 467 724.3
266
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average P/E: 213.6
Negative Multiple: -203.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average EV/EBITDA: 16.4
Negative Multiple: -77.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.3 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Transgene Biotek Ltd
BSE:526139
Average EV/EBIT: 21.5
Negative Multiple: -70.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

See Also

Summary
TRABI intrinsic value, competitors valuation, and company profile.
DCF Valuation
TRABI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TRABI stock valuation using valuation multiples.
Wall Street Estimates
TRABI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TRABI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.